Roche's new breast cancer duo, Perjeta and Kadcyla, seemed destined to make a big splash in the oncology market. Now, Decision Resources has the numbers to show just how big that splash has been.
Itlaian prosecutors have zeroed in on four executives at Roche and Novartis in their probe of potential fraud in the companies' eye-drug sales, Reuters reports, citing sources. The four executives weren't identified.
In another win for Roche, a panel of experts unanimously recommended that the company's HPV test could be used for primary screening of cervical cancer.
Efforts to steer doctors away from off-label use of cancer drug Avastin in favor of the pricier Lucentis for treating sight issues have gotten Swiss drugmakers Roche and Novartis fined by the anticompetition authority in Italy, where prosecutors are also taking a look, and now French regulators say they are in the midst of a probe of their own.
Roche's Ventana Medical Systems and Bayer Pharma have decided to extend and expand a companion diagnostic collaboration first launched in 2012, another steady advance in personalized medicine.
After their antitrust-fighting colleagues levied $251 million in fines against Swiss drugmakers Roche and Novartis on allegations that they colluded to protect sales of their eye drug, Italian prosecutors are now investigating possible market manipulation and fraud, according to Reuters.
Doctors have been prescribing Roche's cancer drug Avastin off-label to treat some of the same vision problems as its eye drug, Lucentis. Now, Italy's antitrust authority has fined Roche and marketing partner Novartis, accusing them of colluding to push doctors toward the pricier option--claims the pair denies.
Roche's lebrikizumab significantly reduced the rate of asthma attacks in patients with a severe form of the disease, according to mid-stage trial results, lighting the way for a Phase III study on the novel, personalized treatment.
Roche's debt from its 2009 buyout of Genentech is winding down--and less money to pay means more money to play with, outgoing chairman Franz Humer says.
With his nearly 20-year stint at Roche coming to an end, longtime Roche Chairman Franz Humer said he's leaving the drugmaker just as it gets out from under Genentech-related debt, clearing the way for some dealmaking and an R&D jump-start.